New Delhi, March 6 -- AstraZeneca India has seen its profit and revenue jump in the past year, driven by a robust product portfolio focused on cancer and non-communicable diseases. The drugmaker's British-Swedish parent has already received 14 product approvals in the past two years, and aims to expedite more launches to bolster its business in India, a top company official said.

"Our first strategy is to bring innovative medicine faster into the country, which otherwise [patients] would go to other parts of the developed world to buy," Sanjeev Panchal, managing director of AstraZeneca India, told Mint in an interview.

The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-...